Gong Kan, Yang Yi, Huang Huan, Kuang Xunjie, Yang Xueqin
Cancer Center, Daping Hospital, Army Medical University, Chongqing 400042, P.R. China.
Mol Clin Oncol. 2021 Oct;15(4):213. doi: 10.3892/mco.2021.2375. Epub 2021 Aug 19.
Despite the success of anti-HER2 therapy in patients with breast cancer with HER2 amplification or HER2 overexpression, the results of clinical trials on anti-HER2 therapy for lung cancer have not been satisfactory. The aim of the present study was to report a case of a non-smoker, female patient diagnosed with stage IIIA lung adenocarcinoma harboring amplification. The disease progressed despite surgery and multiple lines of chemotherapy, plus trastuzumab or lapatinib. The pan-ErbB inhibitor pyrotinib (400 mg/day) was commenced as a fourth-line regimen, and the patient achieved complete response with a time to progression (TTP) of 6 months. After the lung adenocarcinoma progressed, pyrotinib was continued, along with anlotinib and nivolumab. The patient achieved stable disease (SD) status with another 6 months of TTP. The overall survival of the patient was 28 months. Therefore, the present case suggests that the development of novel drugs may provide new and effective therapeutic regimens for lung cancer with HER2 amplification.
尽管抗HER2疗法在HER2扩增或HER2过表达的乳腺癌患者中取得了成功，但抗HER2疗法用于肺癌的临床试验结果并不令人满意。本研究的目的是报告一例非吸烟女性患者，诊断为ⅢA期肺腺癌且伴有HER2扩增。尽管接受了手术、多线化疗以及曲妥珠单抗或拉帕替尼治疗，疾病仍进展。作为四线治疗方案开始使用泛ErbB抑制剂吡咯替尼（400毫克/天），患者获得完全缓解，疾病进展时间（TTP）为6个月。肺腺癌进展后，继续使用吡咯替尼，同时联合安罗替尼和纳武单抗。患者达到疾病稳定（SD）状态，TTP又持续了6个月。患者的总生存期为28个月。因此，本病例表明新药的研发可能为HER2扩增的肺癌提供新的有效治疗方案。
